Dronabinol

Generic Name: Dronabinol

Brand Names: Marinol, Sativex, Syndros

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₂

CAS Number: 1972-08-3

Unique Ingredient Identifier: 7J8897W37S

Background: Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased ...

Indication: Dronabinol is indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Associated Conditions: Anorexia, Chemotherapy-Induced Nausea and Vomiting

Associated Therapies: -

Clinical Trials

Dronabinol Opioid Sparing Evaluation (DOSE) Trial

Phase 2

Conditions: Chronic Pain

Interventions: Drug: Dronabinol

First Posted Date: 2018-12-06

Last Posted Date: 2018-12-06

Lead Sponsor: Daisy Pharma Opioid Venture, LLC

Target Recruit Count: 280

Registration Number: NCT03766269

Locations: 🇺🇸
Daisy Research, Inc., Scottsdale, Arizona, United States

Pilot, Syndros, Decreasing Use of Opioids in Breast Cancer Subjects With Bone Mets

Early Phase 1

Completed

Conditions: Bone Metastases
Breast Cancer
Pain

Interventions: Drug: Syndros

First Posted Date: 2018-09-07

Last Posted Date: 2021-04-29

Lead Sponsor: University of Arizona

Target Recruit Count: 14

Registration Number: NCT03661892

Locations: 🇺🇸
University of Arizona, Tucson, Arizona, United States

Using Imaging to Assess Effects of THC on Brain Activity

Not Applicable

Completed

Conditions: Intoxication Alcohol
Intoxication THC
Intoxication Combined Alcohol THC

Interventions: Drug: Dronabinol
Drug: Placebo dronabinol
Drug: Ethanol
Drug: Placebo ethanol

First Posted Date: 2018-08-31

Last Posted Date: 2022-07-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 316

Registration Number: NCT03655717

Locations: 🇺🇸
Center for Addiction Medicine, Massachusetts General Hospital, Dept. of Psychiatry, Boston, Massachusetts, United States

Tetrahydrocannabinol (THC) and Sleep

Early Phase 1

Active, not recruiting

Conditions: Sleep
THC
Marijuana
Cannabis

Interventions: Drug: Dronabinol

First Posted Date: 2018-06-18

Last Posted Date: 2024-04-15

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 18

Registration Number: NCT03560934

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

Phase 2

Completed

Conditions: Skin-Picking
Trichotillomania

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2018-05-21

Last Posted Date: 2022-06-02

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT03530800

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Effects of THC on Emotional Memory Retrieval

Early Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo oral capsule
Drug: THC

First Posted Date: 2018-03-20

Last Posted Date: 2019-05-30

Lead Sponsor: University of Chicago

Target Recruit Count: 24

Registration Number: NCT03471585

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

Phase 1

Completed

Conditions: Cannabis Use Disorder

Interventions: Drug: THC
Drug: Alprazolam
Drug: Placebo oral capsule
Drug: CBD

First Posted Date: 2018-01-12

Last Posted Date: 2018-06-14

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 42

Registration Number: NCT03398083

Locations: 🇺🇸
Debra Kelsh, MD, Overland Park, Kansas, United States

Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

Early Phase 1

Recruiting

Conditions: Chronic Pain, Widespread

Interventions: Drug: Placebos
Drug: Cannabidiol
Drug: Delta-9-Tetrahydrocannabinol

First Posted Date: 2017-07-12

Last Posted Date: 2024-04-26

Lead Sponsor: University of Utah

Target Recruit Count: 75

Registration Number: NCT03215940

Locations: 🇺🇸
University Of Utah, Salt Lake City, Utah, United States

5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CBD hard capsule dose 1
Drug: CBD hard capsule dose 2
Drug: Sativex

First Posted Date: 2017-06-28

Last Posted Date: 2017-09-20

Lead Sponsor: PhytoTech Therapeutics, Ltd.

Target Recruit Count: 15

Registration Number: NCT03201835

Locations: 🇮🇱
Clinical Research Center (CRC)- Souraskey Medical center, Tel Aviv, Israel

The Role of SAtivex® in Robotic-Rehabilitation

Not Applicable

Completed

Conditions: Rehabilitation

Interventions: Device: Lokomat training
Drug: Sativex

First Posted Date: 2017-06-14

Last Posted Date: 2019-07-26

Lead Sponsor: IRCCS Centro Neurolesi "Bonino-Pulejo"

Target Recruit Count: 40

Registration Number: NCT03186664

Locations: 🇮🇹
IRCCS Centro Neurolesi Bonino-Pulejo", Messina, Sicily, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy